A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P165
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Papadopoulos, Kyriakos P
Tsai, Frank
Hamid, Omid
Xiao, Feng
Steele, Keith E
Rebelatto, Marlon C
Robbins, Paul B
Karakunnel, Joyson J
Lai, Dominic W
Mahipal, Amit
Article History
First Online: 4 November 2015